4.2 Article

A new classification of Diabetic Nephropathy 2014: a report from Joint Committee on Diabetic Nephropathy

Journal

CLINICAL AND EXPERIMENTAL NEPHROLOGY
Volume 19, Issue 1, Pages 1-5

Publisher

SPRINGER
DOI: 10.1007/s10157-014-1057-z

Keywords

Diabetic nephropathy; Chronic kidney disease (CKD); Albuminuria; Proteinuria; Glomerular filtration rate (GFR)

Funding

  1. Astellas Pharma Inc.
  2. Daiichi-Sankyo Co., Ltd.
  3. Mitsubishi Tanabe Pharma Corporation
  4. Takeda Pharmaceutical Co., Ltd.
  5. Novo Nordisk Pharma Ltd.
  6. Merck Sharp Dohme
  7. Boehringer Ingelheim GmbH
  8. Eli Lilly and Company
  9. Japan Tabacco Inc.
  10. Ono Pharmaceutical Co., Ltd.
  11. Project for accelerating Practice and Research on Community Medicine in Okayama Prefecture
  12. Kyowa Hakko Kirin Co., Ltd.
  13. Mochida Pharmaceutical Co., Ltd.
  14. Otsuka Pharmaceutical Co., Ltd.
  15. Teijin Pharma Limited
  16. Baxter International Inc.
  17. Sekisui Medical Co., Ltd.
  18. Chugai pharmaceutical Co., Ltd.
  19. Bayer Yakuhin, Ltd.
  20. Abbott Japan Co., Ltd.

Ask authors/readers for more resources

The Joint Committee on Diabetic Nephropathy has revised its Classification of Diabetic Nephropathy (Classification of Diabetic Nephropathy 2014) in line with the widespread use of key concepts such as the estimated glomerular filtration rate (eGFR) and chronic kidney disease. In revising the Classification, the Committee carefully evaluated, as relevant to current revision, the report of a study conducted by the Research Group of Diabetic Nephropathy, Ministry of Health, Labour and Welfare of Japan. Major revisions to the Classification are summarized as follows: (1) eGFR is substituted for GFR in the Classification; (2) the subdivisions A and B in stage 3 (overt nephropathy) have been reintegrated; (3) stage 4 (kidney failure) has been redefined as a GFR less than 30 mL/min/1.73 m(2), regardless of the extent of albuminuria; and (4) stress has been placed on the differential diagnosis of diabetic nephropathy versus non-diabetic kidney disease as being crucial in all stages of diabetic nephropathy.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available